							ATPR		
Sheet 1 pl 3 ' INFORMATION DISCLOSURE STATEMENT									
FORM PTO 1449 (modified)				ATTY DOCKET NO. 2005_0348A 10/526,494 6 JUN 1 0 2005					
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				APPLICANT					
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				FILING DATE GROUP			ADEMA		
Date Submitted to PTO: June 10, 2005				March 4, 2005					
				S. PATENT DOCUMENT					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLA	SS SUBCLASS	S FILING DATE IF APPROPRIATE		
A	$\left(AA\right)$	5,900,359	5/1999	Matsuura et a	ıl.				
	AB								
			FORE	IGN PATENT DOCUME	NTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLA	SS SUBCLASS	TRANSLATION YES NO		
	AC								
	AD								
\bigcap		OTHER	DOCUMENT(S)	ncluding Author, Title, Da	te, Pertinent Pages,	Etc.)	<u> </u>		
AE K. Kobayashi et al., "A specific ligand for β ₂ -glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages", Journal of Lipid Research, Vol. 42, pp. 697-709, 2001.									
	AF	D. Steinberg et al., "Modification of Low-Density Lipoprotein that Increase its Atherogenicity", The New England Journal of Medicine, Vol. 320, No. 14, pp. 915-924, April 6, 1989.							
9	AG	H. C. Boyd et al., "Direct Evidence for a Protein Recognized by a Monoclonal Antibody against Oxidatively Modified LDL in Atherosclerotic Lesions from a Watanabe Heritable Hyperlipidemic Rabbit", American Journal of Pathology, Vol. 135, No. 5, pp. 815-825, November 1989.							
	АН	Y. Nagano et al., "High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification", Proc. Natl. Acad. Sci., Vol. 88, pp. 6457-6461, August 1991.							
	Al	M. Chang et al., "C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids", PNAS, Vol. 99, No. 20, pp. 13043-13048, October 1, 2002.							
	AJ	H. Kamido et al., "Lipid ester-bound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins", Journal of Lipid Research, Vol. 36, pp. 1876-1886, 1995.							
	AK	G. Hoppe et al., "Oxidation products of cholesteryl linoleate are resistant to hydrolysis is macrophages, form complexes with proteins, and are present in human atherosclerotic lesions", Journal of Lipid Research, Vol. 38, pp. 1347-1360, 1997.							
	AL H. Kamido et al., "Identification of cholesterol-bound aldehydes in copper-oxidized low density liproprotein", FEBS LETTERS, Vol. 304, No. 2 & 3, pp. 269-272, June 1992.								
EXAMINER		h		DATE CO	ONSIDERED	2/4/4	··········		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy this form with next communication to applicant.

								_		
Sheet 2.of 3			INFORMA	TION DISCLOS	SURE STATEMENT			PE		
FORM PTO 1449 (m	TMENT OF COMMERCI		2005_03		10/526,		(g)	ļ		
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				APPLICANT Eiji MATSUURA						
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				FILING DAT	FILING DATE GROUP RADENARY			EMARK		
Date	Submitte	ed to PTO: June 10, 200			March 4, 2005					
				S. PATENT DO		<u> </u>	TT			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	<u>.</u>	NAME			FILING DAT		
	ВА									
			FOR	EIGN PATENT	DOCUMENTS					
		DOCUMENT NUMBER	DATE	cc	DUNTRY	CLASS	SUBCLASS TRANSLATION YES NO			
	вв									
7.00	OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)									
W	ВС	J. Hulthe et al., "Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the atherosclerosis and insulin resistance (AIR) study", Clinical Science, Vol. 100, pp. 371-378, 2001.								
	BD	M. Ryan et al., "Antibodies to oxidized lipoproteins and their relationship to myocardial infarction", Q J. Med, Vol. 91, pp. 411-415, 1998.								
	BE	C. Monaco et al., "Autoantibodies against oxidized low density lipoproteins in patient with stable angina, unstable angina or peripheral vascular disease", European Heart Journal, Vol. 22, pp. 1572-1577, 2001.								
	BF	E. Matsuura et al., "Anticardiolipin Antibodies Recognize β ₂ -Glycoprotein I Structure Altered by Interacting with an Oxygen Modified Solid Phase Surface", J. Exp. Med., Vol. 179, pp. 457-462, February 1994.								
	BG	B. Bouma et al., "Adhesion mechanism of human β ₂ -glycoprotein I to phospholipids based on its crystal structure", The EMBO Journal, Vol. 18, No. 19, pp. 5166-5174, 1999.								
	ВН	M. Hoshino et al., "Identification of the Phospholipid-binding Site of Human β₂-Glycoprotein I Domain V by Heteronuclear Magnetic Resonance", J. Mol. Biol., Vol. 304, pp. 927-939, 1998.								
	Ві	D. Hong et al., "Flexible Loop of β₂-Glycoprotein I Domain V Specifically Interacts with Hydrophobic Ligands", Biochemistry, Vol. 40, pp. 8092-8100, 2001.								
	BJ	Y. Hasunuma et al., "Involvement of β ₂ -glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages", Clin. Exp. Immunol., Vol. 107, pp. 569-573, 1997.								
	вк	L. Kritharides et al., "A Method for Defining the Stages of Low-Density Lipoprotein Oxidation by the Separation of Cholesterol-and Cholesteryl Ester-Oxidation Products using HPLC", Analytical Biochemistry, Vol. 213, pp. 79-89, 1993.								
	BL	J. George et al., "Induction of Early Atherosclerosis in LDL-Receptor-Deficient Mice Immunized with β ₂ -Glycoprotein I", Basic Science Reports, pp. 1108-1114, September 15, 1998.								
EXAMINER					DATE CONSIDER	ED 14	K/17			

Sheet 3.of 3			INFORM	IATION DISCLOSURE STATEMEN	VT 🔷		OIPE	
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S)				ATTY DOCKET NO. 2005_0348A 10/526,494 JUN 1 1 2005				
				APPLICANT Eiji MATSUURA	7.4			
Da	3311.8	eral sheets if necessary) ted to PTO: June 10, 200	15	FILING DATE March 4, 2005		GROUP	40FMABA	
				U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	CA							
			FOF	REIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	СВ			<u> </u>				
		OTHER	DOCUMENT(S)	(Including Author, Title, Date, Perti	tinent Pages, Etc.)			
K	СС	J. George et al., "Im Basic Rapid Commi	munolocaliza unication, pp.	ation of β ₂ -Glycoprotein I (A _I . 2227-2229, May 4, 1999.	polipoprotein H)	to Human Ather	rosclerotic Plaques"	
	CD	E. Matsuura et al., "Proteolytic cleavage of β ₂ -glycoprotein I: reduction of antigenicity and the structural relationship", International Immunology, Vol. 12, No. 8, pp. 1183-1192, 2000.						
	CE	P. Holvoet et al., "Oxidized LDL and Malondialdehyde-Modified LDL in Patients with Acute Coronary Syndromes and Stable Coronary Artery Disease", American Heart Association, pp. 1487-1494, October 13, 1998.						
	CF	K. Ichikawa et al., "A Chimeric Antibody with the Human γ1 Constant Region as a Putative Standard for Assays to Detect IgG β₂Glycoprotein I-Dependent Anticardiolipin and Anti-β₂-Glycoprotein I Antibodies", Arthritis & Rheumatism, Vol. 42, No. 11, pp. 2461-2470, November 1999.						
	CG	A. Ambrozic et al., "Anti-β ₂ -glycoprotein I antibodies in children with atopic dermatitis", International Immunology, Vol. 14, No. 7, pp. 823-830, 2002.						
	СН	Q. Liu et al., "ω-Carboxyl variants of 7-ketocholesteryl esters are ligands for β ₂ -glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages", Journal of Lipid Research, Vol. 43, pp. 1486-1494, 2002.						
	CI			ation of β2GPI on the Plate i aal of Autoimmunity, Vol. 18,			nti-β2GPI	
h	(2)	E. Matsuura et al., "/ pp. 51-66, 2002.	Anti-β ₂ -Glyco	protein I Autoantibodies an	d Atherosclerosi	is", Intern. Rev.	Immunol., Vol. 21,	
-	СК			n I deficiency: prevalence, g herosclerosis, Vol. 152, pp.			n plasma lipoprotein	
	CL			ensity lipoprotein (Ox-LDL) l rndrome (APS)", Clin. Exp. I	Immunol., Vol. 1	08, pp. 227-233		
EXAMINER Y				DATE CONSIDE	ERED 12	14/07		

*EXAMINER: Initial if reference considered. Include copy this form with next communication to applicant.